All In Biotech

Drug Trial Radar · NCT02420379

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy

Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Jun 30, 2015

Primary completion

Dec 17, 2018

Study completion Dec 17, 2018

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • eteplirsenDrug

    Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to DiscontinuationTime frame: Baseline up to 100 weeks
  2. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to 100 weeks
  3. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to 100 weeks
  4. Number of Participants With at Least One Abnormal Physical Examination FindingTime frame: Baseline up to 100 weeks
  5. Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEsTime frame: Baseline up to 96 weeks
  6. Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEsTime frame: Baseline up to 96 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Neuromuscular Research Center of Arizona

    Phoenix, Arizona

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Stanford University Medical Center

    Stanford, California

  • University of Florida, Shands Hospital

    Gainesville, Florida

  • Rare Disease Research Center

    Atlanta, Georgia

  • Children's Hospital of Atlanta

    Atlanta, Georgia

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • St. Louis Children's Hospital

    St Louis, Missouri

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Shriners Hospital for Children

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.